| Year |
Citation |
Score |
| 2023 |
Trivedi T, Manaa M, John S, Reiken S, Murthy S, Pagnotti GM, Dole NS, She Y, Suresh S, Hain BA, Regan J, Ofer R, Wright L, Robling A, Cao X, ... ... Guise TA, et al. Zoledronic acid improves bone quality and muscle function in a high bone turnover state. Biorxiv : the Preprint Server For Biology. PMID 37333318 DOI: 10.1101/2023.06.01.543305 |
0.365 |
|
| 2022 |
Ballinger TJ, Thompson WR, Guise TA. The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health. Breast Cancer Research : Bcr. 24: 84. PMID 36419084 DOI: 10.1186/s13058-022-01576-2 |
0.436 |
|
| 2022 |
Liu H, He J, Bagheri-Yarmand R, Li Z, Liu R, Wang Z, Bach DH, Huang YH, Lin P, Guise TA, Gagel RF, Yang J. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nature Communications. 13: 3684. PMID 35760800 DOI: 10.1038/s41467-022-31356-7 |
0.44 |
|
| 2022 |
Arellano DL, Juárez P, Verdugo-Meza A, Almeida-Luna PS, Corral-Avila JA, Drescher F, Olvera F, Jiménez S, Elzey BD, Guise TA, Fournier PG. Bone microenvironment-suppressed T cells increase osteoclast formation and osteolytic bone metastases in mice. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 35635377 DOI: 10.1002/jbmr.4615 |
0.454 |
|
| 2021 |
Trivedi T, Pagnotti GM, Guise TA, Mohammad KS. The Role of TGF-β in Bone Metastases. Biomolecules. 11. PMID 34827641 DOI: 10.3390/biom11111643 |
0.458 |
|
| 2021 |
Trivedi T, Guise TA. Systemic effects of abnormal bone resorption on muscle, metabolism, and cognition. Bone. 154: 116245. PMID 34718221 DOI: 10.1016/j.bone.2021.116245 |
0.447 |
|
| 2020 |
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R, Costa L. Bone metastases. Nature Reviews. Disease Primers. 6: 83. PMID 33060614 DOI: 10.1038/s41572-020-00216-3 |
0.458 |
|
| 2020 |
Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 33028943 DOI: 10.1038/s41391-020-00296-y |
0.364 |
|
| 2020 |
Seth P, Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang CH, Saha P, Gulukota K, Helseth DL, Guise T, Prabhakar BS, Kaul K, Schreiber H. LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. Human Gene Therapy. PMID 32394753 DOI: 10.1089/Hum.2020.078 |
0.466 |
|
| 2020 |
Ballinger T, El-Azab S, Liu Z, Guise T, Imel E. Abstract P2-08-11: High prevalence and incidence of new onset diabetes in metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-08-11 |
0.459 |
|
| 2019 |
Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G. Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews. Urology. PMID 31712765 DOI: 10.1038/S41585-019-0251-X |
0.364 |
|
| 2019 |
Saito H, Gasser A, Bolamperti S, Maeda M, Matthies L, Jähn K, Long CL, Schlüter H, Kwiatkowski M, Saini V, Pajevic PD, Bellido T, van Wijnen AJ, Mohammad KS, Guise TA, et al. TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone. Nature Communications. 10: 1354. PMID 30902975 DOI: 10.1038/S41467-019-08778-X |
0.443 |
|
| 2019 |
Waning DL, Guise TA, Mohammad KS. A "Connexin" Responsible for the Fatal Attraction of Cancer to Bone. Cell Metabolism. 29: 6-8. PMID 30625309 DOI: 10.1016/J.Cmet.2018.12.014 |
0.476 |
|
| 2018 |
Wright L, Mohammad K, Guise T. Abstract 1808: The anti-estrogen endoxifen altered bone morphology and reduced muscle function in mice Cancer Research. 78: 1808-1808. DOI: 10.1158/1538-7445.Am2018-1808 |
0.516 |
|
| 2017 |
Mohammad KS, Guise TA. Breaking Down Barriers to Chemoresistance: Role of Chemotherapy-Induced Osteoblastic Jagged1. Cancer Cell. 32: 717-718. PMID 29232546 DOI: 10.1016/j.ccell.2017.11.016 |
0.484 |
|
| 2017 |
Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA. Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget. 8: 86447-86462. PMID 29156807 DOI: 10.18632/oncotarget.21200 |
0.471 |
|
| 2017 |
Esposito M, Guise T, Kang Y. The Biology of Bone Metastasis. Cold Spring Harbor Perspectives in Medicine. PMID 29101110 DOI: 10.1101/Cshperspect.A031252 |
0.578 |
|
| 2017 |
Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack JS, ... ... Guise TA, et al. Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases. Cancer Research. PMID 28855208 DOI: 10.1158/0008-5472.Can-17-1225 |
0.548 |
|
| 2017 |
Trivedi T, Zheng Y, Fournier PGJ, Murthy S, John S, Schillo S, Dunstan CR, Mohammad KS, Zhou H, Seibel MJ, Guise TA. The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget. 8: 26687-26701. PMID 28460457 DOI: 10.18632/oncotarget.15803 |
0.348 |
|
| 2017 |
Regan JN, Trivedi T, Guise TA, Waning DL. The Role of TGFβ in Bone-Muscle Crosstalk. Current Osteoporosis Reports. PMID 28161871 DOI: 10.1007/S11914-017-0344-5 |
0.348 |
|
| 2016 |
Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, Kang KS, Carson JA, Guise TA, Mohammad KS, Robling AG, Couch ME, Koniaris LG, Zimmers TA. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Frontiers in Physiology. 7: 679. PMID 28123369 DOI: 10.3389/fphys.2016.00679 |
0.459 |
|
| 2016 |
Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. PMID 28039445 DOI: 10.18632/Oncotarget.14139 |
0.475 |
|
| 2016 |
Zhang P, Xing C, Rhodes SD, He Y, Deng K, Li Z, He F, Zhu C, Nguyen L, Zhou Y, Chen S, Mohammad KS, Guise TA, Abdel-Wahab O, Xu M, et al. Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice. Stem Cell Reports. PMID 27237378 DOI: 10.1016/J.Stemcr.2016.04.013 |
0.326 |
|
| 2016 |
Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, Michou L, Brown JP, Windle JJ, Kurihara N, Roodman GD. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. The Journal of Clinical Investigation. PMID 26878170 DOI: 10.1172/Jci82012 |
0.406 |
|
| 2016 |
Wright L, Harhash A, Waning D, Mohammad K, Marks A, Guise T. Bisphosphonates prevent osteolysis and muscle weakness in aromatase inhibitor-treated mice with breast cancer bone metastases Bone Abstracts. DOI: 10.1530/Boneabs.5.Cabs.Oc4.2 |
0.515 |
|
| 2016 |
Regan J, Waning D, Mohammad K, Mikesell C, Reiken S, Marks A, Guise T. Muscle dysfunction in immune competent mice with osteolytic breast cancer in bone is associated with skeletal muscle oxidation of RyR1 Bone Abstracts. DOI: 10.1530/Boneabs.5.Cabs.Oc4.1 |
0.413 |
|
| 2016 |
Xu W, Yang Y, Neill T, Wang H, Wang C, Yun C, Guise T, Brendler CB, Iozzo RV, Wang L, Seth P. 417. Intratumoral Delivery of Oncolytic Adenovirus Expressing Decorin Inhibits Growth and Metastases of 4T1 Breast Tumors in Syngeneic Immune Competent BALB/c Mice Model Molecular Therapy. 24: S165-S166. DOI: 10.1016/S1525-0016(16)33226-9 |
0.445 |
|
| 2015 |
Regan JN, Waning DL, Guise TA. Skeletal muscle Ca(2+) mishandling: another effect of bone-to-muscle signaling. Seminars in Cell & Developmental Biology. PMID 26593325 DOI: 10.1016/J.Semcdb.2015.11.007 |
0.338 |
|
| 2015 |
Yang Y, Xu WW, Neill T, Hu Z, Wang CH, Xiao X, Stock S, Guise T, Yun CO, Brendler CB, Iozzo RV, Seth P. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases. Human Gene Therapy. PMID 26467629 DOI: 10.1089/Hum.2015.098 |
0.533 |
|
| 2015 |
Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, ... ... Guise TA, et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nature Medicine. PMID 26457758 DOI: 10.1038/Nm.3961 |
0.4 |
|
| 2015 |
Stayrook KR, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PG, Mohammad KS, Waning DL, Guise TA. TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis. Bonekey Reports. 4: 719. PMID 26157579 DOI: 10.1038/Bonekey.2015.88 |
0.52 |
|
| 2015 |
Wu C, Rankin EB, Castellini L, Alcudia JF, LaGory EL, Andersen R, Rhodes SD, Wilson TL, Mohammad KS, Castillo AB, Guise TA, Schipani E, Giaccia AJ. Corrigendum: Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes & Development. 29: 1202. PMID 26063577 |
0.32 |
|
| 2015 |
Waning DL, Guise TA. Cancer-associated muscle weakness: What's bone got to do with it? Bonekey Reports. 4: 691. PMID 25992285 DOI: 10.1038/Bonekey.2015.59 |
0.405 |
|
| 2015 |
Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA. The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell. 27: 809-21. PMID 25982816 DOI: 10.1016/J.Ccell.2015.04.009 |
0.431 |
|
| 2015 |
Wu C, Rankin EB, Castellini L, Fernandez-Alcudia J, LaGory EL, Andersen R, Rhodes SD, Wilson TL, Mohammad KS, Castillo AB, Guise TA, Schipani E, Giaccia AJ. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes & Development. 29: 817-31. PMID 25846796 DOI: 10.1101/Gad.255000.114 |
0.41 |
|
| 2015 |
Wright LE, Buijs JT, Kim HS, Coats LE, Scheidler AM, John SK, She Y, Murthy S, Ma N, Chin-Sinex HJ, Bellido TM, Bateman TA, Mendonca MS, Mohammad KS, Guise TA. Single-Limb Irradiation Induces Local and Systemic Bone Loss in a Murine Model. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 30: 1268-79. PMID 25588731 DOI: 10.1002/Jbmr.2458 |
0.432 |
|
| 2015 |
Buijs JT, Matula KM, Cheung H, Kruithof-de Julio M, van der Mark MH, Snoeks TJ, Cohen R, Corver WE, Mohammad KS, Jonkers J, Guise TA, van der Pluijm G. Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase. The Journal of Pathology. 235: 745-59. PMID 25421310 DOI: 10.1002/path.4488 |
0.402 |
|
| 2014 |
Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, Chirgwin JM. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis. Breast Cancer Research : Bcr. 16: 458. PMID 25439669 DOI: 10.1186/S13058-014-0458-Y |
0.465 |
|
| 2014 |
Wright LE, Guise TA. The microenvironment matters: estrogen deficiency fuels cancer bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2817-9. PMID 24803577 DOI: 10.1158/1078-0432.CCR-14-0576 |
0.525 |
|
| 2014 |
Xu W, Zhang Z, Yang Y, Hu Z, Wang CH, Morgan M, Wu Y, Hutten R, Xiao X, Stock S, Guise T, Prabhakar BS, Brendler C, Seth P. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1504-17. PMID 24791939 DOI: 10.1038/Mt.2014.80 |
0.463 |
|
| 2014 |
Waning DL, Guise TA. Molecular mechanisms of bone metastasis and associated muscle weakness. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3071-7. PMID 24677373 DOI: 10.1158/1078-0432.Ccr-13-1590 |
0.52 |
|
| 2014 |
Xu W, Zhang Z, Guise T, Brendler CB, Seth P. Abstract 723: Liver-detargeted Ad5/48 chimaeric hexon based oncolytic adenovirus targeting TGFβ signaling: A safe and effective approach for the treatment of prostate cancer bone metastases Cancer Research. 74: 723-723. DOI: 10.1158/1538-7445.Am2014-723 |
0.438 |
|
| 2013 |
Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS. Role of TGF-β in breast cancer bone metastases. Advances in Bioscience and Biotechnology (Print). 4: 15-30. PMID 24558636 DOI: 10.4236/Abb.2013.410A4003 |
0.524 |
|
| 2013 |
Waning DL, Mohammad KS, Guise TA. Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell. 24: 407-9. PMID 24135278 DOI: 10.1016/J.Ccr.2013.10.001 |
0.447 |
|
| 2013 |
Guise TA. Breast cancer bone metastases: it's all about the neighborhood. Cell. 154: 957-9. PMID 23993088 DOI: 10.1016/j.cell.2013.08.020 |
0.455 |
|
| 2013 |
Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, ... ... Guise TA, et al. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 2476-89. PMID 23703870 DOI: 10.1002/Jbmr.1992 |
0.329 |
|
| 2013 |
Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. Plos One. 8: e63153. PMID 23696795 DOI: 10.1371/journal.pone.0063153 |
0.495 |
|
| 2013 |
Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, ... ... Guise TA, et al. Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature. 495: 365-9. PMID 23485965 DOI: 10.1038/Nature11929 |
0.319 |
|
| 2013 |
Wright LE, Frye JB, Lukefahr AL, Timmermann BN, Mohammad KS, Guise TA, Funk JL. Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. Journal of Natural Products. 76: 316-21. PMID 23145932 DOI: 10.1021/Np300663V |
0.539 |
|
| 2013 |
Bilezikian JP, Bouillon R, Clemens T, Compston J, Bauer DC, Ebeling PR, Engelke K, Goltzman D, Guise T, Beur SMJD, Jüppner H, Lyons K, McCauley L, McClung MR, Miller PD, et al. Primer on the metabolic bone diseases and disorders of mineral metabolism. Journal of Bone and Joint Surgery-British Volume. 1087-1087. DOI: 10.1002/9781119266594 |
0.358 |
|
| 2012 |
Buijs JT, Stayrook KR, Guise TA. The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Reports. 1: 96. PMID 23951484 DOI: 10.1038/bonekey.2012.96 |
0.476 |
|
| 2012 |
Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Research. 72: 6247-56. PMID 23002206 DOI: 10.1158/0008-5472.CAN-12-1444 |
0.459 |
|
| 2012 |
Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Zhang Z, Du H, Brendler CB, Xiao X, Pienta KJ, Guise T, Lee C, Stern PH, Stock S, et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Human Gene Therapy. 23: 871-82. PMID 22551458 DOI: 10.1089/Hum.2012.040 |
0.489 |
|
| 2012 |
Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Molecular Cancer Research : McR. 10: 597-604. PMID 22522458 DOI: 10.1158/1541-7786.MCR-11-0482 |
0.521 |
|
| 2012 |
Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, Foley J. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. Plos One. 7: e30255. PMID 22276166 DOI: 10.1371/journal.pone.0030255 |
0.49 |
|
| 2012 |
Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 31: 2521-34. PMID 21963846 DOI: 10.1038/Onc.2011.429 |
0.392 |
|
| 2012 |
Rhodes SD, He Y, Chen S, Yang H, Menon KM, Staser K, Yang X, Mohammad KS, Guise T, Xu M, Yang F. Haploinsufficiency of Nf1 in Myeloid Lineages Contributes to Neurofibromatosis Type 1 Associated Skeletal Deficits Blood. 120: 830-830. DOI: 10.1182/Blood.V120.21.830.830 |
0.454 |
|
| 2012 |
Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O. Erratum to: Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis Breast Cancer Research and Treatment. 131: 1085-1086. DOI: 10.1007/S10549-011-1654-4 |
0.527 |
|
| 2011 |
Buijs JT, Stayrook KR, Guise TA. TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 4: 261-81. PMID 21748439 DOI: 10.1007/s12307-011-0075-6 |
0.532 |
|
| 2011 |
Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 2523-36. PMID 21698666 DOI: 10.1002/jbmr.450 |
0.383 |
|
| 2011 |
Buijs JT, Juárez P, Guise TA. Therapeutic strategies to target TGF-β in the treatment of bone metastases. Current Pharmaceutical Biotechnology. 12: 2121-37. PMID 21619539 |
0.487 |
|
| 2011 |
Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nature Reviews. Cancer. 11: 411-25. PMID 21593787 DOI: 10.1038/Nrc3055 |
0.469 |
|
| 2011 |
Liang H, Ma SY, Mohammad K, Guise TA, Balian G, Shen FH. The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model. Spine. 36: 497-504. PMID 21422981 DOI: 10.1097/BRS.0b013e3181d8906f |
0.397 |
|
| 2011 |
Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 2546-55. PMID 21415233 DOI: 10.1093/Annonc/Mdr017 |
0.509 |
|
| 2011 |
Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, Samaras AT, Boyle SN, Bennett CL, West DP, Guise TA. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 560-8. PMID 21288927 DOI: 10.1158/1078-0432.CCR-10-1595 |
0.38 |
|
| 2011 |
Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Research. 71: 175-84. PMID 21084275 DOI: 10.1158/0008-5472.Can-10-2651 |
0.677 |
|
| 2011 |
Juárez P, Guise TA. TGF-β in cancer and bone: implications for treatment of bone metastases. Bone. 48: 23-9. PMID 20699127 DOI: 10.1016/j.bone.2010.08.004 |
0.525 |
|
| 2011 |
Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Research and Treatment. 125: 421-30. PMID 20352489 DOI: 10.1007/S10549-010-0848-5 |
0.561 |
|
| 2011 |
Hoggatt J, Mohammad KS, Chitteti BR, Singh P, Speth JM, Hu P, Poteat B, Srour E, Guise T, Pelus LM. Bone Marrow Niche Attenuation by Non-Steroidal Anti-Inflammatory Drugs Mobilizes Hematopoietic Stem and Progenitor Cells by Differing Mechanisms Blood. 118: 724-724. DOI: 10.1182/Blood.V118.21.724.724 |
0.384 |
|
| 2011 |
Pollari S, Käkönen R, Mohammad KS, Rissanen JP, Halleen J, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise T, Kallioniemi O, Käkönen S. Abstract 845: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis Cancer Research. 71: 845-845. DOI: 10.1158/1538-7445.Am2011-845 |
0.57 |
|
| 2011 |
Guise T. New therapies for cancer-induced bone disease: Preclinical perspective Bone. 48. DOI: 10.1016/J.Bone.2010.10.026 |
0.487 |
|
| 2010 |
Guise T. Examining the metastatic niche: targeting the microenvironment. Seminars in Oncology. 37: S2-14. PMID 21111245 DOI: 10.1053/J.Seminoncol.2010.10.007 |
0.564 |
|
| 2010 |
Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Current Medical Research and Opinion. 26: 3-20. PMID 21050131 DOI: 10.1185/03007995.2010.533162 |
0.486 |
|
| 2010 |
Hu Z, Zhang Z, Guise T, Seth P. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Human Gene Therapy. 21: 1623-9. PMID 20712434 DOI: 10.1089/Hum.2010.018 |
0.443 |
|
| 2010 |
Coenegrachts L, Maes C, Torrekens S, Van Looveren R, Mazzone M, Guise TA, Bouillon R, Stassen JM, Carmeliet P, Carmeliet G. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Research. 70: 6537-47. PMID 20682798 DOI: 10.1158/0008-5472.CAN-09-4092 |
0.492 |
|
| 2010 |
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treatment Reviews. 36: 615-20. PMID 20478658 DOI: 10.1016/J.Ctrv.2010.04.003 |
0.473 |
|
| 2010 |
Juárez P, Guise TA. Tgf-Beta pathway as a therapeutic target in bone metastases. Current Pharmaceutical Design. 16: 1301-12. PMID 20166977 |
0.465 |
|
| 2010 |
Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 29: 811-21. PMID 19915614 DOI: 10.1038/Onc.2009.389 |
0.507 |
|
| 2009 |
Guise TA. Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes & Development. 23: 2117-23. PMID 19759260 DOI: 10.1101/gad.1854909 |
0.526 |
|
| 2009 |
Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. Plos One. 4: e6896. PMID 19727403 DOI: 10.1371/Journal.Pone.0006896 |
0.697 |
|
| 2009 |
Mohammad KS, Fournier PG, Guise TA, Chirgwin JM. Agents targeting prostate cancer bone metastasis. Anti-Cancer Agents in Medicinal Chemistry. 9: 1079-88. PMID 19719455 DOI: 10.2174/187152009789735008 |
0.464 |
|
| 2009 |
Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Molecular and Cellular Endocrinology. 310: 71-81. PMID 19616059 DOI: 10.1016/J.Mce.2009.07.004 |
0.498 |
|
| 2009 |
Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, ... ... Guise TA, et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. Plos One. 4: e5275. PMID 19357790 DOI: 10.1371/Journal.Pone.0005275 |
0.444 |
|
| 2009 |
Brown SA, Guise TA. Cancer treatment-related bone disease. Critical Reviews in Eukaryotic Gene Expression. 19: 47-60. PMID 19191756 |
0.484 |
|
| 2009 |
Casimiro S, Alho I, Fernandes A, Lipton A, Guise T, Costa L. RANKL plays a role in migration and invasion of the bone-seeking cell line MDA-MB-231-BO2 through human type I collagen by up-regulating MMP1. Cancer Research. 69: 2052. DOI: 10.1158/0008-5472.Sabcs-2052 |
0.506 |
|
| 2008 |
Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6387-95. PMID 18927277 DOI: 10.1158/1078-0432.Ccr-08-1572 |
0.459 |
|
| 2008 |
Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treatment Reviews. 34: S19-24. PMID 18486348 DOI: 10.1016/j.ctrv.2008.03.006 |
0.438 |
|
| 2008 |
Mohammad KS, Chirgwin JM, Guise TA. Assessing new bone formation in neonatal calvarial organ cultures. Methods in Molecular Biology (Clifton, N.J.). 455: 37-50. PMID 18463809 DOI: 10.1007/978-1-59745-104-8_3 |
0.381 |
|
| 2008 |
Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss Annals of Oncology. 19: 1407-1416. PMID 18448451 DOI: 10.1093/Annonc/Mdn164 |
0.389 |
|
| 2008 |
Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Reviews in Molecular Medicine. 10: e7. PMID 18321396 DOI: 10.1017/S1462399408000616 |
0.501 |
|
| 2008 |
Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. Cancer Biology & Therapy. 7: 3-9. PMID 18059174 DOI: 10.4161/cbt.7.1.5163 |
0.508 |
|
| 2008 |
Mohammad K, Stebbins E, Kingsley L, Fournier P, Niewolna M, McKenna C, Peng X, Higgins L, Wong D, Guise T. P48. Transforming growth factor β receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases Cancer Treatment Reviews. 34: 37-38. DOI: 10.1016/J.Ctrv.2008.03.106 |
0.507 |
|
| 2008 |
Casimiro S, Alho I, Fernandes A, Lipton A, Guise T, Costa L. P38. RANKL plays a role in migration and invasion of the bone-seeking cell line MDA-MB-231-BO2 and regulates MMP1 and MMP9 expression Cancer Treatment Reviews. 34: 27-28. DOI: 10.1016/J.Ctrv.2008.03.080 |
0.376 |
|
| 2008 |
Fournier P, Clines G, Chirgwin J, Guise T. P32. Transforming growth factor-β (TGF-β) promotes prostate cancer bone metastases: Increased expression of pro-osteolytic genes and of PMEPA1, a new TGF-β signalling regulator Cancer Treatment Reviews. 34: 25. DOI: 10.1016/J.Ctrv.2008.03.074 |
0.416 |
|
| 2008 |
Kingsley L, Fournier P, Chirgwin J, Guise T. P16. Hypoxia and breast cancer bone metastasis: HIF-1α enhances TGF-β signaling and expression of prometastatic factors CXCR4 and VEGF Cancer Treatment Reviews. 34: 18. DOI: 10.1016/J.Ctrv.2008.03.058 |
0.394 |
|
| 2007 |
Brown SA, Clines GA, Guise TA. Local effects of malignancy on bone. Current Opinion in Endocrinology, Diabetes, and Obesity. 14: 436-41. PMID 17982348 DOI: 10.1097/MED.0b013e3282f15419 |
0.486 |
|
| 2007 |
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Molecular Cancer Therapeutics. 6: 2609-17. PMID 17938257 DOI: 10.1158/1535-7163.MCT-07-0234 |
0.475 |
|
| 2007 |
Brown SA, Guise TA. Cancer-associated bone disease. Current Osteoporosis Reports. 5: 120-7. PMID 17925193 |
0.472 |
|
| 2007 |
Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. Journal of Cellular Biochemistry. 102: 1333-42. PMID 17907152 DOI: 10.1002/jcb.21556 |
0.463 |
|
| 2007 |
Fournier PG, Guise TA. BMP7: a new bone metastases prevention? The American Journal of Pathology. 171: 739-43. PMID 17690188 DOI: 10.2353/ajpath.2007.070582 |
0.422 |
|
| 2007 |
Kingsley LA, Chirgwin JM, Guise TA. Breaking new ground to build bone. Proceedings of the National Academy of Sciences of the United States of America. 104: 10753-4. PMID 17581868 DOI: 10.1073/pnas.0704357104 |
0.356 |
|
| 2007 |
Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, André J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Research. 67: 2317-24. PMID 17332363 DOI: 10.1158/0008-5472.Can-06-3950 |
0.477 |
|
| 2007 |
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Fox JW, Chirgwin JM, Guise TA. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology (Baltimore, Md.). 21: 486-98. PMID 17068196 DOI: 10.1210/me.2006-0346 |
0.39 |
|
| 2007 |
Bartholin L, Wessner LL, Chirgwin JM, Guise TA. The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Letters. 246: 230-6. PMID 16616811 DOI: 10.1016/j.canlet.2006.02.019 |
0.446 |
|
| 2007 |
Aapro MS, Hadji P, Brufsky A, Tubiana-Hulin M, Guise T, Body JJ. 2007 POSTER Recommendations for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer Ejc Supplements. 5: 186. DOI: 10.1016/S1359-6349(07)70769-3 |
0.488 |
|
| 2007 |
Ma S(, Choi L, McKenna C, Mohammad K, Li X, Guise T, Shen F. 89. Metastatic Spine Disease: An Isolated Spine Tumor Model with Human Breast Cancer Cells The Spine Journal. 7: 43S-44S. DOI: 10.1016/J.Spinee.2007.07.107 |
0.419 |
|
| 2006 |
Guise TA. Bone loss and fracture risk associated with cancer therapy. The Oncologist. 11: 1121-31. PMID 17110632 DOI: 10.1634/theoncologist.11-10-1121 |
0.394 |
|
| 2006 |
Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6213s-6216s. PMID 17062703 DOI: 10.1158/1078-0432.Ccr-06-1007 |
0.461 |
|
| 2006 |
Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, et al. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6209s-6212s. PMID 17062702 DOI: 10.1158/1078-0432.Ccr-06-1213 |
0.475 |
|
| 2006 |
Seth P, Wang ZG, Pister A, Zafar MB, Kim S, Guise T, Wakefield L. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Human Gene Therapy. 17: 1152-60. PMID 17032151 DOI: 10.1089/Hum.2006.17.1152 |
0.434 |
|
| 2006 |
Guise TA. Do markers of bone turnover predict clinical outcome in patients with bone metastases? Nature Clinical Practice. Endocrinology & Metabolism. 2: 258-9. PMID 16932296 DOI: 10.1038/ncpendmet0171 |
0.377 |
|
| 2006 |
Fournier PG, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Current Opinion in Rheumatology. 18: 396-404. PMID 16763461 DOI: 10.1097/01.bor.0000231909.35043.da |
0.467 |
|
| 2006 |
Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH. NCCN Task Force Report: Bone Health and Cancer Care. Journal of the National Comprehensive Cancer Network : Jnccn. 4: S1-20; quiz S21-2. PMID 16737674 |
0.425 |
|
| 2006 |
Chirgwin JM, Guise TA. Does prostate-specific antigen contribute to bone metastases? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1395-7. PMID 16533760 DOI: 10.1158/1078-0432.CCR-06-0005 |
0.301 |
|
| 2005 |
Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Research. 65: 11001-9. PMID 16322249 DOI: 10.1158/0008-5472.Can-05-2630 |
0.325 |
|
| 2005 |
Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Research. 65: 7320-7. PMID 16103083 DOI: 10.1158/0008-5472.Can-05-1403 |
0.357 |
|
| 2005 |
Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. Journal of Mammary Gland Biology and Neoplasia. 10: 169-80. PMID 16025223 DOI: 10.1007/s10911-005-5399-8 |
0.53 |
|
| 2005 |
Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clinical Breast Cancer. 5: S46-53. PMID 15807924 |
0.53 |
|
| 2005 |
Aris RM, Guise TA. Cystic fibrosis and bone disease: are we missing a genetic link? The European Respiratory Journal. 25: 9-11. PMID 15640316 DOI: 10.1183/09031936.04.00125804 |
0.436 |
|
| 2005 |
Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O'Brien K, Tullis E, Watts NB, White TB. Guide to bone health and disease in cystic fibrosis. The Journal of Clinical Endocrinology and Metabolism. 90: 1888-96. PMID 15613415 DOI: 10.1210/Jc.2004-1629 |
0.361 |
|
| 2005 |
Titus B, Chirgwin J, Guise T, Hampton G, Theodorescu D. 595: The Metastasis Suppressor Gene RhoGDI2 Reduceslung Metastasis in Human Bladder Cancer Via Downregulation of Endothelin 1 Journal of Urology. 173: 163-163. DOI: 10.1016/S0022-5347(18)34835-3 |
0.346 |
|
| 2004 |
Costa L, Fernandes A, Oliveira AG, Leitzel K, Ali S, Schaller J, Demers L, Guise T, Lipton A. Parathyroid hormone-related protein (PTHrp) expression in human bone metastases (BM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9696. PMID 28016071 DOI: 10.1200/Jco.2004.22.14_Suppl.9696 |
0.475 |
|
| 2004 |
Clines GA, Guise TA. Mechanisms and treatment for bone metastases. Clinical Advances in Hematology & Oncology : H&O. 2: 295-302. PMID 16163196 |
0.517 |
|
| 2004 |
Guise TA, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treatment and Research. 118: 197-212. PMID 15043194 |
0.475 |
|
| 2003 |
Padalecki SS, Weldon KS, Reveles XT, Buller CL, Grubbs B, Cui Y, Yin JJ, Hall DC, Hummer BT, Weissman BE, Dallas M, Guise TA, Leach RJ, Johnson-Pais TL. Chromosome 18 suppresses prostate cancer metastases. Urologic Oncology. 21: 366-73. PMID 14670546 DOI: 10.1016/S1078-1439(03)00013-9 |
0.355 |
|
| 2003 |
O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clinical Orthopaedics and Related Research. S100-4. PMID 14600598 DOI: 10.1097/01.Blo.0000093847.72468.2F |
0.397 |
|
| 2003 |
Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clinical Orthopaedics and Related Research. S67-74. PMID 14600594 DOI: 10.1097/01.blo.0000093047.96273.4e |
0.521 |
|
| 2003 |
Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinical Orthopaedics and Related Research. S32-8. PMID 14600590 DOI: 10.1097/01.blo.0000093055.96273.69 |
0.499 |
|
| 2003 |
Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Seminars in Oncology. 30: 717-23. PMID 14571419 |
0.409 |
|
| 2003 |
Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceedings of the National Academy of Sciences of the United States of America. 100: 10954-9. PMID 12941866 DOI: 10.1073/Pnas.1830978100 |
0.523 |
|
| 2003 |
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3: 537-49. PMID 12842083 DOI: 10.1016/S1535-6108(03)00132-6 |
0.455 |
|
| 2003 |
Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 97: 779-84. PMID 12548575 DOI: 10.1002/cncr.11129 |
0.456 |
|
| 2002 |
Gallwitz WE, Guise TA, Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. The Journal of Clinical Investigation. 110: 1559-72. PMID 12438453 DOI: 10.1172/JCI11936 |
0.41 |
|
| 2002 |
Wysolmerski JJ, Dann PR, Zelazny E, Dunbar ME, Insogna KL, Guise TA, Perkins AS. Overexpression of parathyroid hormone-related protein causes hypercalcemia but not bone metastases in a murine model of mammary tumorigenesis. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 17: 1164-70. PMID 12096830 DOI: 10.1359/jbmr.2002.17.7.1164 |
0.496 |
|
| 2002 |
Guise T, Yin JJ, Thomas RJ, Dallas M, Cui Y, Gillespie MT. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo Bone. 30: 670-676. PMID 11996903 DOI: 10.1016/S8756-3282(02)00685-3 |
0.501 |
|
| 2001 |
Padalecki SS, Guise TA. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Research : Bcr. 4: 35-41. PMID 11879558 DOI: 10.1186/bcr415 |
0.516 |
|
| 1999 |
Lemieux P, Harvey J, Guise T, Dallas M, Oesterreich S, Yin JJ, Selander K, Fuqua S. Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo. Journal of Bone and Mineral Research. 14: 1570-1575. PMID 10469286 DOI: 10.1359/Jbmr.1999.14.9.1570 |
0.588 |
|
| 1998 |
Mundy GR, Guise T. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and osteolytic bone disease Endocrine-Related Cancer. 5: 15-26. DOI: 10.1677/Erc.0.0050015 |
0.567 |
|
| Show low-probability matches. |